BGB-21447
- Generic Name
- BGB-21447
Follicular Lymphoma Pipeline Shows Promise with Over 55 Therapies in Development
• The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies.
• Key players like Incyte, AstraZeneca, and Johnson & Johnson are evaluating novel drugs, including CAR-T therapies and targeted agents, to improve patient outcomes.
• Tafasitamab is expected to have a supplemental Biologics License Application filed in August 2024 for patients who have failed prior therapies.
• Emerging therapies in the pipeline include TQ-B3525, NKTR-255, and Zilovertamab vedotin, targeting various mechanisms to combat follicular lymphoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath